VEGFA and infarction: However, its systemic administration is associated with long-term side effects and poses challenges in specifically targeting the heart.361 In 2013, Zangi et al.360 designed modRNA encoding VEGF-A and found that a single intracardial infusion of VEGF-A modRNA could increase the density of blood vessels around infarction, reduce infarct size and cell death.